Analysts point to Definium psychedelic’s MDD efficacy on Phase III success

The rapid onset and durability of response from Definium's psychedelic, DT120 could offer notable benefits in MDD, say analysts and researchers. The rapid onset and durability of response triggered by DT120 could significantly benefit patients with MDD, say analysts and researchers. Definium’s LSD-based psychedelic, DT120, has posted a Phase III win in MDD, which has piqued the interest of researchers and analysts alike. Credit: Alphavector / Shutterstock.com. Following the first late-stage win in a Phase III programme evaluating Definium Therapeutics’ lysergic acid diethylamide (LSD)-based psychedelic in major depressive disorder (MDD), analysts and researchers are touting the drug’s potential as a…

Source: Clinical Trials Arena